Cocrystal Pharma (NASDAQ:COCP – Get Free Report) will likely be releasing its earnings data before the market opens on Thursday, March 27th. Analysts expect Cocrystal Pharma to post earnings of ($0.55) per share for the quarter.
Cocrystal Pharma Trading Down 6.3 %
Shares of NASDAQ:COCP opened at $1.48 on Wednesday. Cocrystal Pharma has a twelve month low of $1.35 and a twelve month high of $3.26. The company has a market cap of $15.06 million, a PE ratio of -0.80 and a beta of 2.35. The company’s 50 day moving average is $1.84 and its 200 day moving average is $1.94.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reissued a “buy” rating and set a $7.00 target price on shares of Cocrystal Pharma in a report on Wednesday, January 22nd.
Cocrystal Pharma Company Profile
Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections.
Further Reading
- Five stocks we like better than Cocrystal Pharma
- The Role Economic Reports Play in a Successful Investment Strategy
- Innovation Incubators: Survey of Entrepreneurs Reveals The Cities Most Supportive of Startups
- How to Calculate Inflation Rate
- NVIDIA Insiders Sell: This Is What It Means for the Market
- Are Penny Stocks a Good Fit for Your Portfolio?
- Space Stocks Bottoming: Which Are Positioned Best for a Bounce?
Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
